Supplementary Data for: Highly selective, allosteric inhibition of TYK2 with oral ESK 001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging Phase 2 study
Published: 2 July 2025| Version 1 | DOI: 10.17632/zs5xvkwpym.1
Contributors:
Andrew Blauvelt, Petr Arenberger, Maxwell B Sauder, Megan Couvillion, Roman G Rubio, Nicholas E Vlahakis, Sibel Ucpinar, Grace Ma, Elena Hitraya, Mera K Tilley, Kim A PappDescription
This dataset contains supplementary data for the following publication: Highly selective, allosteric inhibition of TYK2 with oral ESK 001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging Phase 2 study published in the Journal of the American Academy of Dermatology. Supplementary material includes patient eligibility criteria, list of investigators, and 7 supplementary figures.
Files
Categories
Tyrosine Kinase Inhibitor, Psoriasis, Clinical Trial Results